Stockreport

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Mural Oncology plc - Ordinary Shares  (MURA) 
PDF WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigation [Read more]